Sabuwar fata ga masu fama da cutar Alzheimer? Bari mu yi magana game da wannan sabon magani (Donanemab).

Idan wani a cikin iyalinka, wataƙila mahaifiyarka, mahaifinka, ko kakarka, tana fama da cutar Alzheimer, mun san yadda zai iya zama mai zafi. Abin baƙin ciki ne ganin tunawa da ƙaunataccenka ya ɓace a hankali. Duk da haka, a tsakiyar wannan mawuyacin hali, muna magana ne game da wani labari wanda ke kawo ɗan bege. Wannan ba cikakken magani ba ne ga cutar, amma yana iya zama muhimmin mataki na gaba.

Menene wannan sabon labari?

Kwanan nan, wani kwamitin ba da shawara na Hukumar Abinci da Magunguna ta Amurka (FDA) ya ba da haske gaba ɗaya game da sabon maganin cutar Alzheimer. Sunan maganin shine donanemab . Ana ba da shawarar ga marasa lafiya a farkon matakin cutar. Amincewar wannan kwamitin ba da shawara yana nufin cewa akwai babban yuwuwar cewa FDA za ta ba da cikakken amincewa ga wannan maganin nan ba da jimawa ba. Wannan babban abu ne, domin isowar sabuwar magani ga wata cuta mai tsanani kamar cutar Alzheimer babban bege ne.

Ta yaya Donanemab ke aiki?

To, yanzu bari mu ga yadda wannan maganin yake aiki. Wannan abu ne mai ɗan rikitarwa, amma zan yi bayani a taƙaice. Donanemab wani nau'in magani ne da ake kira monoclonal antibody . A taƙaice dai, wani furotin ne na musamman da aka yi a dakin gwaje-gwaje don kai hari ga wani takamaiman hari ta amfani da sassan tsarin garkuwar jikinmu. Menene manufar wannan maganin? Amyloid plaques ne, waɗanda ake tsammanin su ne babban dalilin cutar Alzheimer. Kamar yadda tsatsa ke taruwa a cikin bututun ruwa, waɗannan plaques suna taruwa tsakanin ƙwayoyin jijiyoyi a cikin kwakwalwa kuma suna tsoma baki a cikin aikinsu. Abin da Donanemab ke yi shi ne gano waɗannan plaques kuma yana taimakawa wajen cire su.

Yaya wannan maganin yake da tasiri?

A bisa ga sakamakon gwaje-gwajen asibiti da aka buga a bara, wannan maganin zai iya rage saurin da cutar ke ta'azzara cikin 'yan watanni.Ya yiwu. Ana auna wannan ta hanyar gwaje-gwajen da ke auna ƙwarewar hankali na marasa lafiya (misali, ƙwaƙwalwa, magance matsaloli) da kuma yadda suke gudanar da ayyukan yau da kullun (misali, tuƙi, sarrafa kuɗi). Wasu ƙwararru suna kiran waɗannan sakamakon sakamako masu sauƙi ko "na al'ada". Wannan yana nufin ba za ku iya tsammanin babban bambanci daga wannan ba. Amma kuma yana da kyau cewa cutar za ta iya raguwa cikin 'yan watanni kaɗan, maimakon ta tsananta ba tare da wani magani ba. Dangane da yadda ake ba da maganin, ana ba wa marasa lafiya magani kowane wata ta hanyar jijiya (jiko). Waɗanda suka shiga gwajin an ba su wannan maganin na tsawon shekara ɗaya da rabi.

Akwai fa'idodi da kuma manyan haɗari.

Kamar kowace magani mai ƙarfi, donanemab yana da fa'idodi da kuma mummunan illa da haɗari. Yana da mahimmanci a fahimci ɓangarorin biyu kafin yanke shawara. Duk da waɗannan la'akari, kwamitin ba da shawara na FDA a ƙarshe ya yanke shawarar cewa fa'idodin wannan maganin sun fi haɗarin da ke tattare da shi.Wato, idan aka ba wa marasa lafiya da suka dace, a ƙarƙashin kulawar da ta dace, fa'idodin sun fi yawa.

Shin wannan ne kawai sabuwar maganin da ake da shi?

A'a. Akwai wani magani da ke aiki ta hanya makamancin haka. Ana kiransa lecanemab . Wannan maganin kuma yana aiki ta hanyar niyya ga ƙwayoyin platelets da ke taruwa a cikin kwakwalwa. Ya sami amincewar FDA a watan Yulin 2023. Donanemab wani mataki ne na wannan tafiya. Manyan ƙungiyoyin Alzheimer na duniya suna da babban bege ga sabbin magunguna kamar wannan. Suna cewa, "Gwargwadon yadda aka amince da irin wannan magani, hakan zai ƙara yawan damar marasa lafiya da suka cancanta. Ana samun ci gaba bayyananne dangane da magani." A halin yanzu, miliyoyin mutane a duniya suna fama da cutar Alzheimer. Har yanzu babu wata hanyar da za a iya hana ko warkar da wannan cuta gaba ɗaya. Saboda haka, magunguna kamar donanemab muhimman matakai ne a cikin wannan dogon tafiya. Cutar Alzheimer, donanemab, cututtukan kwakwalwa, asarar ƙwaƙwalwa, ciwon hauka, sabbin magunguna, maganin rigakafi na monoclonal